Kronos Bio to present data at ASH annual meeting on p300 KAT inhibitor program
The Fly

Kronos Bio to present data at ASH annual meeting on p300 KAT inhibitor program

Kronos Bio (KRON) announced that it will present preclinical data from its p300 KAT inhibitor program for multiple myeloma at the American Society of Hematology, ASH, Annual Meeting taking place in San Diego, California from December 7 to 10, 2024. Data demonstrates Kronos Bio’s approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App